The outlook for patients who present with advanced stage ovarian cancer or who relapse following chemotherapy is poor, despite the advances in cytotoxic chemotherapeutic options that have been achieved over the past decade. The average overall 5-year survival for this group of patients is less than 30% and treatment is primarily palliative.
By identifying which cellular pathways are altered in your patient’s tumor, the Tumor Blueprint can help you prioritize the treatments that are most likely to be effective, based on targeting of the affected pathways.
Clearity will work with you and your patient to enable incorporation of information from her molecular profile into your decision-making as you prioritize therapy options. We can also help you identify appropriate clinical trials for which your patient may be eligible.
